Abercrombie & Fitch on Monday raised its annual net sales growth target for the current quarter helped by strong demand for ...

promises a dynamic and challenging year for businesses as key antitrust cases set new precedent, private antitrust litigation will intensify, ...

In the quest for weight loss, many individuals explore products promising rapid results. Among them, Mitolyn has emerged as a noteworthy contender. This weight loss support supplement is designed to ...

Small- and mid-sized companies have consistently trailed large caps, but UBS believes that may change. Here are 40 top ...

There has been tremendous interest in cell-based meat, not least for its touted long-term potential to aid world food security.

Maintaining good eyesight is more critical than ever in today's fast-paced world. With rising screen time and environmental ...

Discover how smart energy meters enhance solar systems, ensuring accurate billing, maximized feed-in tariffs, and optimized ...

BofA raised the firm’s price target on Intra-Cellular (ITCI) to $118 from $100 and keeps a Buy rating on the shares after the company announced a favorable Caplyta patent settlement with Sandoz ...

On Friday, BofA Securities analyst Jason Gerberry increased the price target on Intra-Cellular Therapies (NASDAQ:ITCI) to $118 from the previous $110, while maintaining a Buy rating for the ...

On Monday, Mizuho (NYSE:MFG) Securities updated its financial outlook for Intra-Cellular Therapies (NASDAQ:ITCI), increasing the stock's price target from $100 to $140 while maintaining an ...

The Dow Jones Industrial Average climbed Monday, outperforming the market, while the Nasdaq Composite slipped as traders ...